Lucid Dreaming Is a New State of Consciousness, Scientists Find
After analyzing many previous studies on lucid dreaming, researchers have defined it as a state that differs significantly from both REM sleep and wakefulness.
The awareness of dreaming during a lucid dream is now thought to come from shifts in brain wave activity undergone by several parts of the brain, including the right central lobe, parietal lobe and precuneus.
Lucid dreams were also found to have effects similar to psychedelics like LSD.
Have you ever had a dream in which you realized you were dreaming?
When you become conscious of the fact that you are dreaming, you can take advantage of that knowledge and manipulate the dream. If you want to do something that is physically impossible in the real world, such as flying, you can leap into the air and take flight. Someone who realizes they are trapped in a nightmare can convince themselves to wake up.
The state known as lucid dreaming is an unquestionably surreal one, and it just got even more so. A team of researchers—led by Çağatay Demirel from the Donders Center for Cognitive Neuroimaging at Radboud University Medical Center, the Netherlands—has discovered that lucid dreaming has now been found to be a state of consciousness separate from both wakefulness and REM sleep (the state usually associated with dreams), and is in fact associated with its own unique type of brain activity. They published a study on their findings in the Journal of Neuroscience.
'This research opens the door to a deeper understanding of lucid dreaming as an intricate state of consciousness by pointing to the possibility that conscious experience can arise from within sleep itself,' Demirel said in a press release.
To identify what sets lucid dreaming apart from the rest of sleep, he and his team pulled previous studies—in which brain activity was measured with EEG sensors—together into what is now the most extensive dataset in this field of sleep research. The researchers then compared brain activity patterns for wakefulness, REM sleep, and lucid dreaming to find that that the eerie self-awareness experienced in lucid dreams has a connection to the electrical rhythms in neurons known as brain waves.
Perception and memory processing in the lucid dreaming state were found to be different from non-lucid REM sleep. The consciousness of existing in a dream was associated with with beta waves in the right central lobe (which controls spatial awareness and nonverbal memory) and parietal lobe (which controls the sense of touch and spatial awareness). Beta waves are a type of high-frequency electromagnetic activity in the brain involved in conscious thought processes like solving problems or making decisions. Our consciousness is dominated by beta waves when we are awake.
This might explain why there is so much cognitive control in lucid dreams. Dreamers deep in REM sleep have no sense of control over factors like thoughts, feelings, and behaviors, but those in lucid dreaming states do.
Demirel also linked gamma waves with lucid dreaming. These are the fastest brain waves, which become visible on an EEG at times when the brain is especially alert and focusing on something. When lucid dreaming begins, gamma waves increase in the right precuneus, which is involved in self-referential thinking—thoughts about ourselves and our lives. When we are awake, we often drift into this type of thinking when our minds wander.
Maybe the most mind-bending thing about lucid dreams is that they are, according to the study, similar in the brain to the effects of psychedelic drugs such as LSD and ayahuasca. These types of psychedelic experiences are also associated with the precuneus, whose activity is modified when waking imagery is seen despite having closed eyes (something usually only experienced with psychedelics). Interestingly, however, lucid dreams may even go a few experiential steps past psychedelics. 'While psychedelics often lead to a dissolution of ego and decreased self-referential processing […] lucid dreams may actually harness elements of self-awareness and control,' Demirel and his team said in the study.
So if you're capable of lucid dreaming, you're in for an awesome trip.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
an hour ago
- Hamilton Spectator
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
Collaboration will leverage Key2Brain's technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on a partnership initiated in 2022, supporting continued development led by positive in vivo proof-of-concept data demonstrating the potential of Key2Brain's technology PARMA, Italy and STOCKHOLM, June 11, 2025 (GLOBE NEWSWIRE) — Chiesi Group and Key2Brain today announced a worldwide license agreement to advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD), including alpha-mannosidosis (aMann) and Krabbe disease (KD), ultra-rare diseases that affect the central nervous system. The agreement also includes a framework for the parties to include additional enzymes into the collaboration, enabling the expansion of Chiesi's BBB-crossing ERT portfolio and further strengthening its development capabilities. The advancement of these programs will also contribute to Key2Brain's goal of establishing its technology as a leading BBB-crossing platform. At Chiesi Group, these programs are spearheaded by Chiesi Global Rare Diseases, the Group's dedicated business unit focused on research, development, and commercialization of therapies for rare and ultra-rare conditions. 'At Chiesi Global Rare Diseases, we are deeply committed to building a sustainable pipeline in rare diseases by embracing emerging technologies that can enhance the treatment landscape,' said Giacomo Chiesi, Executive Vice President, Chiesi Global Rare Diseases. 'This agreement exemplifies that vision— working to address areas of profound unmet medical need, including neurodegenerative manifestations of ultra-rare diseases like alpha-mannosidosis and Krabbe disease. For too many families, there are still no therapeutic options. Our goal is to bring them hope.' Under the terms of the agreement, Key2Brain will provide Chiesi Group with a worldwide, royalty- bearing license to develop and commercialize two BBB-crossing ERTs. This agreement is built on an existing research collaboration that aimed to develop the production of a BBB-crossing recombinant alpha-mannosidase. Key2Brain will receive an upfront payment and is eligible to receive development and sales-based milestone payments and tiered royalties on potential sales. Chiesi Group will fund all research, development, and subsequent commercialization worldwide. As part of this agreement, there is also a possibility, upon mutual agreement, for the parties to expand the license to Key2Brain's BBB-crossing technology platform for the development of additional BBB-crossing ERTs. 'This exciting collaboration continuation with Key2Brain represents a strategic opportunity to build on the progress we've already made together,' said Mitch Goldman, Senior Vice President R&D, Chiesi Global Rare Diseases. 'By combining our deep therapeutic expertise with Key2Brain's proprietary BBB-crossing platform technology, we aim to enhance the biodistribution, efficacy and tolerability of promising therapies that have historically faced challenges reaching the central nervous system. Together, our goal is to unlock new therapeutic pathways for patients with lysosomal storage disorders, ultimately delivering meaningful and lasting innovation.' Elisabet Sjöström, Ph.D., Founder and CEO, Key2Brain, said, 'Expanding our relationship with Chiesi Global Rare Disease allows us to build on a clinically validated foundation to address the neurological complications of lysosomal storage disorders, including alpha-mannosidosis and Krabbe disease. Through this agreement, we aim to accelerate the research of potential breakthrough therapies that address these neurodegenerative conditions. We believe this partnership serves as a testament to the versatility and competitiveness of our BBB-crossing technology, unique features that are being utilized in Key2Brain's development of our proprietary next-generation brain-targeting therapies.' This collaboration leverages Key2Brain's proprietary BBB-crossing platform technology and Chiesi Global Rare Diseases' capabilities and expertise in this ultra-rare disease landscape, creating a path to advance the ongoing aMann-K2B program as well as initiate new preclinical programs that apply Key2Brain's technology to other LSDs. About Chiesi Group Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi's commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For more information visit: About Chiesi Global Rare Diseases Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit: . Follow @ChiesiGlobalRareDiseases on LinkedIn, Facebook, Instagram, X and YouTube. About Key2Brain Key2Brain is a Swedish biotechnology company dedicated to developing next generation brain targeting therapeutics utilizing its proprietary blood-brain barrier-crossing (BBB-crossing) technology. The technology enables efficient brain uptake and broad distribution of CNS-therapeutics, utilizing small and flexible antibody fragments (VHHs). Key2Brain's VHHs can be integrated into a wide range of therapeutic molecules. The pipeline is being developed internally and in partnerships where Key2Brain's team leverages extensive industry experience in biologics and brain-targeting drugs, accelerating the translation from discovery to the clinic. Key2Brain was founded 2020 and is based in Stockholm. For more information visit: About Key2Brain's technology platform Key2Brain's technology enables efficient brain uptake and broad distribution of therapeutics, utilizing small (<15kDa) engineered single domain VHH antibodies with monovalent specificity for the Transferrin Receptor (TfR). The technology provides opportunities for the development of next generation brain targeting across a diverse range of therapeutic areas. Key2Brain's VHH technology can be efficiently integrated into or combined with therapeutic molecules without impacting either the disease target specificity, or the binding of transferrin to TfR. The modular and flexible platform is being applied to peptides, proteins, enzymes, and oligonucleotides. Key2Brain's VHHs can be expressed in both prokaryotic and eukaryotic systems and purified using commercial large-scale affinity purification systems. The proprietary platform includes species cross-reactive (human/primate/mouse) as well as human/primate specific binders together with a humanized TfR mouse model for translational studies. Chiesi Global Rare Diseases Media Contact Sky Striar LifeSci Communications sstriar@ Key2Brain Media Contact Benjamin Nordin, CBO Key2Brain
Yahoo
8 hours ago
- Yahoo
How a WVU student discovered a fungus that could help treat addiction, depression
MORGANTOWN, (WBOY) — Following her discovery of a life-changing fungus earlier this year, 12 News spoke with West Virginia University student Corrine Hazel and her professor on how they came across the fungus that's eluded scientists for nearly a century. Hazel wasn't looking to discover a new species. She was working on a research project that involved morning glories, a fungus known for dispersing a protective chemical called 'ergot alkaloids.' But one day, something caught her eye, little bits of fuzz on the inside of some seed coats. Hazel's professor, Daniel Panaccione, is the Davis Michael Professor of Plant and Soil Science at WVU and has been studying ergot alkaloids for years. In the 1930s, scientist Albert Hofmann altered an ergot alkaloid from a morning glory plant to create the hallucinogenic, LSD. He thought that it actually must've been a fungus on the plant that produces the chemical, but he could never find it. For almost a century, no one could find it, even though they knew it must be there. Panaccione and Hazel realized they could have the missing fungus. 'We didn't want to get our hopes up too high,' Panaccione said. 'We had some level of skepticism until we had a lot more data, but inside I was excited.' WVU Board of Governors voting to extend President Gordon Gee's contract, but only by a few weeks To confirm that this was a new species, the pair had to figure out the fungus's entire DNA sequence and see how different it was from other fungi. Hazel said extracting a full DNA sample required some trial and error. 'I guess I never really knew how much, like, trial and error went into the process just to get your experiments to work. Sometimes, you have to try quite a few times,' Hazel said. When the pair got the DNA sequence back from the lab, it was official. This was, in fact, a new species of fungus—likely the one that eluded Hofmann in his day. They named it 'Periglandula clandestina,' as the word 'clandestine' means 'something kept secret.' Professor Panaccione said that in his more than 30 years of research, this is the first time he has discovered a new fungus. The discovery yields new possibilities, as ergot alkaloids are known for their medical properties. 'This fungus makes such high quantities of those chemicals, and by expressing the genes in an organism like yeast, you could recombine them and make new versions or make greater quantities, and the chemicals are used to treat dementia, migraine, and a variety of other conditions,' Panaccione said. The WVU team has found, though, that Periglandula clandestina doesn't like to grow away from the morning glories. Why and how to get it to grow is a new question for WVU faculty and students to look into. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
16 hours ago
- Yahoo
When Letting Your Mind Wander Helps You Learn
While you do the dishes or drive to work, your mind is likely not on the task at hand; perhaps you're composing a grocery list or daydreaming about retiring in Italy. But research published in the Journal of Neuroscience suggests you might be taking in more than you think. During a simple task that requires minimal attention, mind wandering may actually help people learn probabilistic patterns that let them perform the task better. 'The idea to study the potentially beneficial influence of mind wandering on information processing occurred to us during the COVID pandemic, when we had plenty of time to mind wander,' says Péter Simor, lead author of the recent study and a psychology researcher at Eötvös Loránd University in Budapest. Study participants practiced a simple task in which they pressed keyboard buttons corresponding to the direction of arrows that lit up on a screen. But there were patterns hidden within the task that the participants were unaware of—and they learned these patterns without consciously noticing them. The researchers found that when participants reported letting their minds wander, they adapted to the task's hidden patterns significantly faster. [Sign up for Today in Science, a free daily newsletter] 'This is an exciting and important piece of work, especially because the authors opted for a nondemanding task to check how [mind wandering] would affect performance and learning,' says Athena Demertzi, a cognitive and clinical neuroscientist at the University of Liège in Belgium. Previous related research focused more on long and demanding tasks, she says—on which zoning out is typically shown to have a negative effect. But the results are not clear-cut, says Jonathan Smallwood, a psychology researcher at Queen's University in Kingston, Ontario. 'I don't think that this means the spontaneous mind-wandering episodes themselves cause implicit learning to occur,' he says. 'Rather both emerge at the same time when people go into a particular state.' Neither Smallwood nor Demertzi was involved in the new study. Simor, who studies sleep, was interested in whether participants' mind wandering displayed any neural hallmarks of dozing off. Using electroencephalogram recordings, the team showed that in those test periods, participants' brains produced more of the slow waves that are dominant during sleep. Perhaps, the researchers say, mind wandering is like a form of light sleep that provides some of that state's learning benefits. To better understand whether mind wandering might compensate for lost sleep, Simor and his colleagues next plan to study narcolepsy and sleep deprivation. 'We know that people spend significant amounts of time not focused on what they are doing,' Smallwood says. 'The authors' work is important because it helps us understand how reasonably complex forms of behavior can continue when people are focused on other things—and that even though our thoughts were elsewhere, the external behavior can still leave its mark on the person.'
